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Synopsis 
This work presents a Systems and a Network Medicine view of Crohn’s and Ulcerative Colitis (UC). This work 
has identified distinctly different genes and molecular processes involved in each disease, which were used to 
find potential drug targets, as well as novel candidate drugs. 
 
Abstract 
Crohn’s Disease (CD) and Ulcerative Colitis (UC), both under the umbrella of Inflammatory Bowel Diseases 
(IBD), involve many distinct molecular processes. The difference in molecular processes is studied using the 
different genes involved in each disease, and explored further for drug targeting and drug repurposing. 
 
Methods 
We have created a manually curated one-stop-shop informatics database (IBD-Omics) of genes, SNPs, drugs, 
biomarkers and microarray studies involved in CD and UC. This curated database was created by mining 
published literature, published studies such as the Genome Wide Association Studies (GWAS). The identified 
genes were then subject to informatics analytics software such as IPA, to reveal their molecular processes. A 
network pharmacology approach has identified newer targets and drugs that can be repurposed. 
 
Results 
We found that CD involved the Th1 pathway, while UC involved the Th2 pathway. Further analysis on gene 
networks demonstrated that dyslipidemia, epigenetic modulations and dysbiosis play a key role in CD, while 
inflammation, angiogenesis and potential carcinogenesis processes are involved in UC. Further, this dysbiosis 
and dyslipidemia in CD is associated with microbiome population change, suggestive of altered levels of 
micronutrients. Finally, using extended networks based on metabolomics and protein-protein interactions, we 
were able to suggest a role for synergistic approach in guiding treatment for CD and UC. 
 
Conclusion 
We demonstrate using the Systems and Network Medicine approach that CD and UC are distinct diseases 
with unique sets of genes that define them. We find novel molecular connections that can be explored for 
therapeutic and clinical purposes. 
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BACKGROUND 
Inflammatory Bowel Disease (IBD) is generally an umbrella term used to describe chronic 
inflammation found in the lining of the intestinal tract. IBD encompasses two major diseases—
Crohn’s Disease (CD) and Ulcerative Colitis (UC) [1-4]. CD may present transmurally in any part 
of the gastrointestinal system. It generally occurs in the ileum of the small intestine as well as the 
beginning of the large intestine. UC is confined to the mucosal layer of the colon [5]. They are 
both known to be multifactorial diseases, with complex etiologies and risk factors. In the clinic, it 
remains difficult to differentiate between the two because they could present in the same areas of 
the intestine with similar symptoms. The current medications generally prescribed for UC and CD 
belong to the classes of anti-inflammatory drugs, corticosteroids, immunomodulators and 
antibodies [6-13]. Several of these drugs come with their own side-effects 
(https://www.drugs.com/sfx/). In addition to these standardized treatments, integrative medicine 
that includes yoga and herbal therapies is taking center stage [14-16].  
 
These two diseases have proven difficult to understand due to the multifactorial nature of each 
disease. Twin studies have revealed a proband concordance rate in monozygotic twins of around 
58-62% for CD and 6-18% for UC, indicating a strong environmental influence on disease 
pathogenesis [17-20]. The interaction between the human immune system and the microbiome in 
the gut has recently been getting more attention [4, 21-23].  Due to IBD’s (CD and UC) complexity 
in its origins, traditional laboratory methods have so far been ineffective in teasing out any 
substantial information on IBD. The advent of high throughput sequencing technologies has 
allowed for the leveraging of in-silico research methods like Genome Wide Association Studies 
(GWAS), which have identified over 160 IBD associated genetic loci [24]. This knowledge, 
however, has not translated yet into a cure for CD and UC. The coupling of other “omics” 
techniques (Proteomics, Metabolomics, Transcriptomics, etc.) will allow researchers to obtain a 
more holistic view of pathogenesis in ways unavailable several years ago.  
 
The aim of this paper is to present a novel Systems Medicine holistic view to explore these diseases. 
This includes –omics analysis (Genomics, proteomics, metabolomics, microbiome), text-mining, 
and a novel systems network pharmacology approach to identify potential synergistic drugs and 
drug-targets [25]. We are in an era of network and systems medicine, where “one-size fits all” does 
not work. Drugs are developed for an “average” person and often fail in many individuals. We are 
still practicing a trial and error approach and we fail to understand the drug that works precisely in 
a patient.  
 
In the pre-genomic era, CD and UC were simply clubbed as IBD. The post-genomic era has 
delineated IBD into CD and UC.  In order to avoid any confusion, we will consider genes that are 
not classified into CD or UC as IBD-unclassified. While there are a number of common genes 
shared between the diseases (IBD-unclassified, CD and UC), the goal of this paper is to focus on 
the differences between what defines UC and CD specifically to identify pathways that may 
distinguish them, and thus point to newer treatment modalities and targets.  
 
We have established a database, IBD-Omics, a manually curated database solely devoted to IBD-
unclassified, CD and UC. It contains only literature validated information for genes, proteins, 
SNP’s, biomarkers and miRNA, as well as links to relevant GEO microarray expression datasets, 
drugs and current clinical trials. Also located within the database are two powerful tools UDsome 
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(Uniprot Diseasome) and GDsome (GWAS Diseasome), which leverage the UniProt database and 
GWAS databases [26, 27], respectively, to mine data the user wants using simple text searches. 
We hope this will evolve to become a one-stop shop for researchers focused on IBD, CD and UC. 
We utilized the data in the database to first explore the granular understanding of UC and CD, 
relating to molecular events and disease progression. Further, we used analytics software Ingenuity 
Pathway Analysis (IPA) tool  to provide a more holistic view of CD and UC. Thirdly, we have 
applied a novel systems network pharmacology approach to provide a mechanistic view of the 
diseases and to point to newer drugs and targets.  
 
 
RESULTS 
Canonical Pathway Analysis of genes from Master List for CD, UC and IBD-Unclassified 
 
CD Involves Th1 while UC involves Th2 Activation and Differentiation Pathways 
 
Following the lesson that there exists a significant relationship between activated genes and 
molecular events that may lead to inflammatory diseases, we analyzed the genes that were involved 
in CD, UC and IBD-unclassified as noted in our master list (Supplementary_Table1.xlsx) using 
IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). 
These genes are non-redundant and not shared between CD, UC and IBD-Unclassified. Genes not 
shared were used to highlight the differences between CD and UC, so newer drug targets specific 
to CD and UC maybe easier to find. IPA was used to map the genes to pathways (Table 1) and for 
identification of gene regulators (Table 2). The list of genes belonging to each of the top 5 
canonical pathways for CD and UC is provided in Table 3.  
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Table 1:  Top 5 statistically enriched canonical pathway analysis for CD, UC, IBD-Unclassified 
identified using IPA. The p-value signifies the statistical significance of the pathways mapped. A 
p-value of <0.5 is taken as statistically significant.  
 
  
CD CD p-value UC 
UC 
p-value 
IBD-
Unclassified 
IBD-
Unclassified 
p-value 
TREM1 Signaling  1.02E-08  Systemic Lupus 
Erythematosus in B 
Cell 
Signaling Pathway 
7.61E-23  Th17 
Activation 
Pathway 
8.66E-19 
Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 
1.34E-08  Role of Pattern 
Recognition Receptors 
in 
Recognition of 
Bacteria and Viruses 
1.08E-19 IL-23 Signaling 
Pathway 
2.41E-18 
Role of Cytokines in 
Mediating 
Communication 
between Immune Cells  
8.94E-08  Hepatic Cholestasis 2.16E-18  Systemic Lupus 
Erythematosus 
In B Cell 
Signaling 
Pathway 
1.86E-17 
Neuroinflammation 
Signaling Pathway 
1.70E-07  Th17 Activation 
Pathway 
5.02E-18 Role of 
Cytokines in 
Mediating 
Communication 
between 
Immune Cells 
2.28E-17 
T Helper Cell 
Differentiation 
4.12E-07  HMGB1 Signaling 1.28E-17 T Helper Cell 
Differentiation 
5.75E-16 
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Table 2:  Top 5 statistically significant upstream regulators of the top 5 pathways provided in 
Table 1 for CD, UC, IBD-Unclassified based on IPA. The p-value signifies the statistical 
significance of the pathways mapped. A p-value of <0.5 is taken as statistically significant. 
CD CD  p-value UC 
UC  
p-value 
IBD-
Unclassified 
IBD-
Unclassified 
p-value 
NFkB (complex) 2.49E-12 IFNG 7.43E-
36 
Peptidoglycan 1.86E-19 
Lipopolysaccharide 1.25E-11 Lipopolysaccharide 6.44E-
31 
IFNG 2.03E-19 
Glucocorticoid 2.56E-11 TNF 1.60E-
29 
SOCS3 1.76E-18 
Resiquimod 3.75E-10 IL6 9.41E-
29 
Misoprostol 4.76E-18 
TLR4 4.22E-10 IL10 4.85E-
28 
IL23 5.06E-18 
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Table 3: Genes from our Master list in the Top Canonical pathways as per IPA for CD and UC 
 
   
Based on the IPA results, it is clear that CD and UC have distinctive pathways that define them. 
CD is driven by the Th-1 pathway, and UC by Th-2 pathway and an altered epithelial barrier 
function [28].  The interplay between innate and adaptive immunity plays a key role in both CD 
and UC and both are under the cross regulation of these responses. The genes and pathways 
provided in Table 1 correlate well with what we know from the literature. For example, TREM-1 
is an important signaling receptor on Neutrophil or Macrophage leading to chemokine and 
cytokine induction by interacting with DAP12 [29]. Further, TREM-1 is part of the signaling 
pathways induced by Pattern Recognition Receptors TLR and NLR. Through the literature we 
know TLR5 and TLR10 are innate immunity genes identified to be involved in CD, which are part 
of the TREM1 signaling pathway [29]. Specifically, the binding of flagellin to TLR5 is well known 
to stimulate an immune response in patients with CD. In addition, ICAM1, IL27, TYK2 all lead 
to the differentiation of the T cells to Th1. 
 
Other genes, for example, Tyk2 and Jak2 are involved in both CD and UC. Tyk2 and Jak2 is 
required for the differentiation of Th1 cells from naïve T cells [30]. CD28 promotes the production 
of Th2 differentiation, which then activates the humoral response, making both processes involved 
in UC and CD. This suggests that there seems to be several different components of inflammation 
involved with CD and UC and these are regulated by different sets of genes (Table 2).  
  
CD Genes (CD) UC Genes (UC) 
TREM1 Signaling  
ICAM1, IL10, IL18, 
NOD2, TLR10, 
TLR5, TNF 
Systemic 
Lupus 
Erythematosus 
in B Cell 
Signaling 
Pathway 
FCGR2A,IL13,IL2,IL21,IL25,IL33,IL6,IRF5,JAK
2,KRAS,NFATC1,NFKB1,PIK3CG,PLCG2,PTPN
11,RAC1,RELA,STAT3,TGFB1, TNFSF15 
Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 
FCGR3A/FCGR3B, 
ICAM1, IL10, IL16, 
TNF 
IL18, SOCS3, 
TLR10, TLR5, 
TNFRSF1A 
 
Role of Pattern 
Recognition 
Receptors in 
Recognition of 
Bacteria and 
Viruses 
CLEC7A, IL13, IL2, IL21, IL25, IL33, IL6, 
NFKB1, NOD1, PIK3CG, PLCG2, RELA, 
TGFB1, TLR4, TNFSF15 
 
Role of Cytokines in 
Mediating 
Communication between 
Immune Cells  
IFNA10, IFNA4, IL10, 
IL18, IL27 
TNF 
Hepatic 
Cholestasis 
ABCB1, ADCY7, CD14, HNF4A, IL13, IL2, IL21, 
IL25, IL33, IL6, NFKB1, RELA, TGFB1, TLR4, 
TNF, TNFSF15 
 
Neuroinflammation 
Signaling Pathway 
ICAM1, IFNA10, 
IFNA4, IL10, IL18, 
TLR10, TLR5, 
TNFRSF1A, TNF 
 
Th17 
Activation 
Pathway 
CCL20,CCR6,DEFB4A/DEFB4B,IL21,IL22,IL23
R,IL6,JAK2,NFATC1,NFKB1,RELA,STAT3,STA
T4 
T Helper Cell 
Differentiation 
IL10, IL18, IL23R, 
IL2RA, TNFRSF1A, 
TNF 
 
HMGB1 
Signaling 
IL13, IL2, IL21, IL25, IL33, IL6, KRAS, NFKB1, 
PIK3CG, RAC1, RELA, TGFB1, TLR4, TNF, 
TNFSF15 
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Systems and Network Pharmacology approach for identification of newer targets to enable 
drug-repurposing 
Single target symptom based treatment of diseases with one drug for the disease has not proven 
effective. Here we have applied a more mechanistic network based approach that was recently 
published in the literature [25]. This approach is an integrative multilayered molecular network.  
This approach starts with one causal gene target and extends to protein metabolite interacting 
partners (co-targets). A causal gene (i.e. specific to CD or UC) directly interacts with multiple 
metabolites. Such metabolites also interact with other proteins. There are situations where such 
pairs of proteins that involve common metabolites may behave in synergy (guilt by association) 
and result in pairing synergistic mechanistic disease targets enabling systems medicine based drug 
repurposing. 
 
For CD, Tumor Necrosis Factor (TNF) was chosen as a causal clinical target because of its 
involvement in the activation of Th1 cells and its central role as a drug target in the treatment of 
CD. The results for CD show involvement of multiple Histone deacetylases (HDACs), specifically 
HDAC 2,3,4,5 (Table 4). The role of epigenetics in IBD has been known for decades. CD and UC 
are more common among certain sections of the population. For example, a study carried out on 
the geographic origins of Jewish patients with IBD found that IBD genes are more prevalent in 
those who originated from mid-Europe than those of Polish and Russian origin [31]. Our analysis 
points to an important role of epigenetics in CD.  
 
HDAC3 regulates many genes that are transcriptional targets of PPAR-nuclear receptors, which is 
also significantly involved as a protein interacting partner in CD (Table 4). HDACs are involved 
in regulation of immune systems and some have positive influence on antigen-presenting cell 
(APC), production of IL12 leading to differentiation of Th1. This is in concordance with the 
involvement of Th1 in CD (Table 1) [32]. While further studying the network associated with CD 
surrounding TNF, it was revealed that the immediate protein clusters are all involved with Th1 
activity consistent with Table 1.  
 
The results of the network analysis led to interacting partners that all have a common metabolite 
and also are currently drug-targets with already approved drugs for other disease conditions, 
paving the way for drug-repurposing [30, 33].  Additionally, IL16 leads to Th1 mediated 
inflammation [34]; IL18 in the presence of IL12 promotes Th1 production of IFNγ further driving 
the Th balance towards Th1 [35]. ATG16L1 is a protein known to have mutant form T300A, which 
result in abnormal Paneth cells. These altered Paneth cells experienced increased Endoplasmic 
Reticulum (ER) stress markers, and patients with such abnormal Paneth cells harbored adherent-
invasive E Coli [36]. Thus, we can infer that the immediate protein cluster surrounding TNF 
promotes epigenetic changes, as well as Th1 development, which drives the CD state. We propose 
that the CD state involves epigenetic changes that lead to dysbiosis and potentially altered levels 
of micronutrients such as SCFA that affect the colonic environment, which lead to more pro-
inflammatory states. 
 
For UC, Vascular Endothelial Growth Factor A (VEGFA) was chosen as a causal target, because 
it is known to be a key mediator of angiogenesis and a promising target for UC. The results for 
UC showed proteins involved in acute phase reactants (e.g. NPPB, F10) (Table 5) [37, 38]. 
Heparanase was shown to be involved in UC as well as in a mouse-model of Dextran-induced 
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colitis, where the protein contributed to sensitization of macrophage towards colonic flora leading 
to a pro-inflammatory state [39]. It is notable that one of a key set of proteins involved in external 
environment sensing, Dectin-1, is part of the unique UC gene-set that we found 
(Supplementary_Table1.xlsx). The results also show a cluster of proteins connected: TGFB1, 
FGF2, APOE, or FN1-FGF1; leading to angiogenesis. While FGF2 has a role in repair of intestinal 
epithelium it is notable that FGF2 can induce angiogenesis in the setting of inflammation leading 
to disbiosis [40, 41].  The other end of the network involves players such as LCN2, IL1B, VCAM1, 
or NFkB1which are known genes involved in inflammation. The protein NGAL encoded by LCN2 
is shown to be closely correlated with an inflamed IBD state, suggesting that the UC network 
involves active inflammation derived from VEGFA [42]. Additionally, the UC network associated 
with VEGFA demonstrates involvement of PTPN11, SOCS3, genes involved in inflammation. 
Aberrant expressions of SHP2 (encoded by PTPN11) and SOCS3 expression in multiple disease 
models led to carcinogenesis by induction of STAT3/IL6 pathways including ulcerative colitis 
[43-45]. The UC disease network also contains a cluster that involves RAC1, TLR4, APRC2, and 
PLCG2. Many of these proteins are surface related proteins involved in inflammatory response 
[46]. Specifically, RAC1 has the potential to be a therapeutic biomarker for thiopurine [47] and 
ARPC2 is seen as a contributory locus to UC susceptibility [48]. Taken together, this suggests a 
disease model of UC: antigens and colonic flora cause the initial inflammatory step, sensed by 
ECM receptors as Dectin-1 which then release proinflammatory cytokines as IL1B. This leads to 
activation of macrophage, which promote more inflammatory states through heparinase activity. 
IL1B is a downstream effector of the Dectin-1 pathway [49]. Additionally, this inflammation 
results in angiogenesis and potential carcinogenesis. 
 
The results of the network pharmacology approach have identified a list of targets and drugs that 
work synergistically (Table 4, Table 5). This opens doors to a combination therapy approach, 
especially because of the complete ineffectiveness of immunotherapy and other drugs currently 
used in the clinic [50]. Our data suggests that anti-TNF therapy is effective for CD but not for UC. 
In fact, some adverse effects have been seen in UC patients treated with anti-TNF antibodies [51]. 
For example, the combination therapy for CD based on our analysis, might be using anti-TNF 
(adalimumab) and Pioglitazone in synergy and anti-VEGFA antibodies and Gallium Nitrate 
(targeting IL1B) for UC. Pioglitazone targets PPAR, have shown to be effective in in-vivo mouse 
studies on colitis models [52, 53]. Gallium Nitrate (targeting IL1B), may be a potential therapeutic 
agent in UC.  
  
In Search of Newer Targets for IBD: A Systems and a Network Medicine Approach 
 
Page 9 of 23 
 
Table 4:  CD-associated network proteins ranked according to their connectedness to TNF via 
their metabolites. Results of Semantic-similarity ranking based on Molecular Functions (MF 
SemSem. An R value cutoff of 0.6 was used.  Many of these genes are epigenetic modulators. 
CD-
associated 
Genes 
Protein Name R 
values DRUGS DISEASE 
TNF Tumor necrosis factor 
(Causal Gene) 
1  
Adalimumab  
Rheumatoid arthritis; 
Intermittent 
claudication;  
HDAC5 Histone deacetylase 5 0.712 PMID29671355- 
Compound-62 
NA 
 
HDAC4 Histone deacetylase 4 0.699 Quisinostat Huntington disease; 
ALPL Alkaline phosphatase, 
tissue-nonspecific 
isozyme 
0.645  
Asfotase alfa 
Genetic disease; 
Parasitic infection;  
AHCY Adenosylhomocysteinase 0.645 Neplanocin A  NA 
HDAC3 Histone deacetylase 3 0.624 CHR-3996 Solid tumour/cancer; 
NGF Beta-nerve growth factor 0.623  
Tanezumab  
Alzheimer disease; 
Chronic pain;  
HDAC2 Histone deacetylase 2 0.608 CHR-3996 Dermatitis; Solid 
tumour/cancer; 
PPARG Peroxisome proliferator-
activated receptor 
gamma 
0.6  
Pioglitazone  
Type-2 diabetes; 
Hepatosteatosis 
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Table 5:  UC-associated network proteins ranked according to their connectedness to VEGFA via 
their metabolites. Results of Semantic-similarity ranking based on Molecular Functions (MF 
SemSem. An R value cutoff of 0.61 was used.  Many of these genes are acute-phase reactants, as 
well as pro-inflammatory molecules. 
UC- 
associated 
Gene 
Name R Values DRUGS DISEASE 
VEGFA Vascular endothelial growth factor A 1 Ranibizumab  Solid tumour/cancer; 
FN1 Fibronectin 0.736 Ocriplasmin Colorectal cancer; Symptomatic 
vitreomacular adhesion 
IL1B Interleukin-1 beta 0.716 Gallium 
nitrate 
Immune System disease; 
Hypercalcaemia;  
NPPB Natriuretic peptides B 0.693 BD-NP  Hypertension 
APP Amyloid beta A4 protein 0.691 
Florbetapir  
F-18 
Alzheimer disease; Cerebral 
amyloid angiopathy 
ANG Angiogenin 0.674 Citric Acid 
APOB Apolipoprotein B-100 0.659 SPC4955 High blood cholesterol level 
FGF1 Heparin-binding growth factor 1 0.657 CVBT-141H  
Coronary artery disease; Peripheral 
arterial disease 
SERPINC1 Antithrombin-III 0.648 Enoxaparin Venous thrombosis; Thrombosis 
APOE Apolipoprotein E 0.641 AEM-28 Hyperlipidaemia; Familial hypercholesterolemia; 
FGF2 Heparin-binding growth factor 2 0.633 Sucralfate  
Neurodegenerative disorder; 
Diabetic retinopathy;  
HPSE Heparanase 0.625 PG-545  Angiogenesis disorder; Ocular disease; 
ADRA1A Alpha-1A 
adrenergic receptor 0.622 Xatral  
Major depressive disorder; 
Glaucoma/ocular hypertension;  
VCAM1 Vascular cell 
adhesion protein 1 0.615 Carvedilol Blood pressure; heart failure 
F10 Coagulation factor X 0.611 Apixaban Thrombosis; Hemophilia 
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Protein-Protein Interacting networks: Putting it all together 
Combining data from our master list and the results of our network pharmacology approach 
(Tables 1, 2, 3, 4, and 5) we created a combined network to further understand the mechanism in 
CD and UC (Figures 1a and 1b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a: Protein-protein interaction network of all identified genes for CD using String-DB [54]. Genes 
identified by our network pharmacology approach is starred (*Druggable targets). Colored nodes indicate 
first shell interactions.  Edges represent protein-protein associations. Blue indicates that the information 
is from curated databases; pink experimentally determined; Green is gene neighborhood; dark blue 
represents gene co-occurrence, yellow is from text mining; black represents co-expression. Proteins with 
no interactions are not included in the figure for clarity. 
 
 
 
 
 
 
 
In Search of Newer Targets for IBD: A Systems and a Network Medicine Approach 
 
Page 12 of 23 
 
 
 
Figure 1b: Protein-protein interaction network of all identified genes for UC using String-DB [54]. Genes 
identified by our network pharmacology approach is starred (*Druggable targets). Colored nodes indicate 
first shell interactions.  Edges represent protein-protein associations. Blue indicates that the information 
is from curated databases; pink experimentally determined; Green is gene neighborhood; dark blue 
represents gene co-occurrence, yellow is from text mining; black represents co-expression. Proteins with 
no interactions are not included in the figure for clarity. 
 
Altered microbiome of intestine may be associated with altered micronutrient in the gut 
The Enteric environment becomes significantly altered in the aforementioned manner in the 
context of IBD, leading to altered microbiome when compared to the healthy counterparts, 
especially with CD. We were hoping to characterize this dysbiosis, in hopes of identifying more 
changes that could explain the pro-inflammatory states seen in CD and UC. Disbiome is a database 
that houses microbial composition changes in 354 different diseases [55]. We extracted fecal 
microbiome as a surrogate for intestinal microbiome; and from this we studied the intestinal 
microbiome of CD and UC. The significantly changed microbiome species and their relative 
elevation or reduction from the control has been summarized (Table 6). 
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Table 6: Fecal microbiota for CD and UC from Disbiome database. “Elevated” refers to species elevated 
compared to control groups. “Reduced” refers to species reduced compared to control groups. 
 
 
 
 
 
 
 
CD_Elevated 
Species 
Ruminococcus gnavus 
Clostridium cluster XIVa 
Dipodascus 
Lactobacillales  
Bifidobacterium 
Entyloma 
Bacteroides-Prevotella group 
Actinomyces 
Candida albicans 
Enterococcus 
Akkermansia Municiphila 
 
 
 
 
 
 
 
 
CD_Reduced 
 
 
 
 
 
 
Clostridium leptum 
Bacteroides 
Subdoligranulum 
Parabacteroides 
Citrobacter 
Bacteriodes uniformis 
Enterobacter 
Lactobacillus 
Prevotella 
Eubacterium 
Faecalibacterium 
 
UC_Elevated 
Dipodascus 
Lactobacillales  
Entyloma 
Wallemia 
 
 
UC_Reduced 
Roseburia hominis 
Lactobacillus 
Hanseniaspora 
Blautia coccoides 
Bifidobacterium 
Faecalibacterium 
Prausnitzii 
Clostridium leptum 
Faecalibacterium  
Bacteroides 
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There were some taxa that were elevated in CD while reduced in UC (e.g. bifidobacterium), 
suggesting there may be disease-state specific changes conducive to such population change. This 
may be associated with the difference in the activated disease proteins and pathways, e.g. 
activation of macrophage and altered lipidome in CD vs heparinase in UC. Also, Faecalibacterium, 
associated with healthy state microbiome, were decreased in both CD and UC states (Table 6). On 
the contrary, Ruminococcus gnavus is often found in IBD, associated with inflammatory states and 
shown in-vitro to promote inflammation [56]. This organism was found to be elevated in CD, but 
not in UC (Table 6). Other literature reported that CD seemed to experience more dysbiosis and 
unstable microbiome composition than UC – our data shows CD seems to have more species with 
altered composition than UC. Further in-depth analysis is needed before fully understanding the 
specific roles of species in disease states. 
 
 
Discussion 
Our integrated informatics approach sheds light on the significant differences between CD and UC, 
as well as involvement of intestinal dysbiosis that may contribute to disease states. This analysis 
derived a potential mechanistic view of the CD and UC states, as well as of multi-drug therapeutic 
regimens. As far as we know, this is one of the first works to suggest a polypharmacological 
therapy approach to both CD and UC. The drug therapy suggestions were in concordance with 
prior published works, as our therapy suggestions are based on the drugs that showed efficacy in 
animal trials of colitis. The dysbiosis are also in concordance with other prior works, and offer an 
insight into how dysbiosis is playing a role in the disease state as well as how the disease state 
affects the microbiome. 
 
We found that CD involved the Th1 pathway, while UC involved the Th2 pathway. Further 
analysis on the metabolite-shared protein-protein network led us to demonstrate that dyslipidemia 
and dysbiosis may play a key role in CD, while inflammation, angiogenesis, and potential carcinogenesis 
processes are involved in UC.  
 
Notably our data on CD sheds light on the potential involvement of altered micronutrient level in 
the gut environment. HDAC (as shown to be involved in CD from out Network Pharmacology 
approach) is also involved with changes in lipid metabolism in the gut environment. HDAC3 
deletion in the mouse model led to increased mitochondrial and peroxisomal b-oxdation, fatty acid 
oxidation, and reduction in long-chain fatty acids [57]. This led to regulation of lipid metabolism 
in intestinal epithelium, resulting in remodeling of lipidome of intestinal enterocytes resulting in 
protection from diet-induced obesity. The same histone deacetylatses involved in lipid dysbiosis 
are also affected by the Short Chain Fatty Acids (SCFA) generated by Akkermansia Municiphila, 
or sulforaphane cysteine by Bacteroides thetaiotaomicron [58, 59]. This suggests that HDAC may 
be involved in a feedback loop to itself by regulating the host enteric environment.  
 
For UC, it is interesting to emphasize the involvement of IL1B in its disease state. Dectin-1 is 
activated through fungi/mycobacterial pathogens leading to transcription of IL1B, which is 
important in Th17 differentiation [49]. This is consistent with our protein disease network analysis 
that showed involvement of IL1B. Furthermore, the finding regarding UC is in-line with our 
conventional knowledge of UC, as we see significant association of UC with cancerous events, 
e.g. colonic cancer [60]. This is consistent with our finding that UC is associated molecularly with 
angiogenic events. 
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IBD-Omics, the database introduced here, contains literature validated data for genes, proteins, 
SNPs and miRNA from various sources as GWAS, relevant GEO datasets, drugs and current 
clinical trials, and other pharmacological databases. Marrying such data with analytic algorithms 
allowed molecular understanding of CD and UC. We hope that this approach further advances the 
efforts to utilize the Systems and Network approach for understanding diseases. This also clearly 
has demonstrated, via examples, how layered approaches are needed in delineating CD and UC 
and has led to the identifications of newer targets. 
 
Furthermore, as a community, we must focus the effort on collecting disparate types of information, 
e.g. drug information associated with their molecular targets, more verified and focused molecular 
processes, and cast a wider net of gene lists to increase our knowledge for understanding these 
diseases. Such an approach made possible the probable polypharmaceutical regimen presented 
here, as well as the understanding into the dysbiosis that IBD may cause. Such an approach would 
facilitate the identification of new therapeutic targets for IBD and the understanding of the 
molecular basis of these targets. 
 
 
Materials and Methods 
Literature Mining: Genes, miRNA, SNPs and biomarkers implicated in UC, CD and IBD were 
mined from literature using the text-mining tool Linguimatics (https://www.linguamatics.com/) and 
direct searches using Pubmed (https://www.ncbi.nlm.nih.gov/pubmed). Curated databases like 
DisGenet, Uniprot and NCBI-Refseq were used to filter the huge amount of articles retrieved. Each 
of the genes and its sources thus obtained was reviewed manually to ensure the validity of the 
gene’s involvement in the disease. Table 4 gives a total count of articles retrieved and the results 
of curation of the articles over the years 1966-2019.  
 
Table 7: Total count of Articles curated for Genes, biomarkers, SNPs and miRNA in IBD, CD, UC 
Search terms used IBD CD UC 
Genes 3060 972 526 
Biomarkers 191 59 48 
SNP 1470 1094 531 
miRNA 189 82 75 
Curated 
Information    
Genes 67 31 61 
Biomarkers 24 15 18 
SNP 24 91 87 
miRNA 22 39 37 
 
The process of curation involved reading each article to ascertain its relevance and role in IBD, 
CD and UC, respectively, as proven by experimentation. It must be pointed out that during the pre-
genomic era, CD and UC were simply referred to as IBD. The distinction between them was 
adapted in the literature only in the last decade after the completion of the human project and the 
availability of data from other projects.  
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 GWAS Catalog: The data presented in this manuscript was obtained from the GWAS catalog. 
The catalog was downloaded from https://www.ebi.ac.uk/gwas/downloads on April 28,2020. 
[61, 62]. 
 
Genes implicated in IBD, CD and UC were obtained by filtering the Disease/Trait column of the 
catalog and searching for Inflammatory Bowel Disease, Ulcerative Colitis and Crohn’s disease 
individually. Since the goal of GWAS is to identify causative-SNPs in the genes, we included only 
the genes where a missense variant was identified. We have not included the genes that carried 
SNPs in the intronic, intergenic and the regulatory regions because limited mechanistic 
information available on their roles in disease progression. The IBD-OMICS database however 
has this information. 
 
Master List: A master list of Genes was created by combining the list of genes obtained from the 
manually curated set derived from the literature, Curated Genes from DisGenet database [63] and 
those obtained from GWAS. The duplicate genes between the different data sorces were removed 
from the master list.  From this master list, a unique set of genes for CD and UC was obtained for 
disease specific analysis. Only genes that mapped to a Uniprot Accession were retained. The 
master list of genes is in Supplementary_Table1.xlsx. A total of 50 genes were obtained for CD, 
83 for UC and 57 genes for IBD.  The IBD genes are the common set of genes between CD and 
UC. Some of the genes could give us clues about IBD-indeterminate genes. However, 
identification of IBD-indeterminate gene analysis is beyond the scope of this paper. IPA was used 
to map the genes in our master list to pathways. IPA provides detailed mapping to top canonical 
pathways and provides upstream and downstream regulators.  
 
Protein-Protein Interactions Network: String database was used to create protein-protein networks 
[54].  
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Systems Medicine and Network Pharmacology Analysis workflow:  
 
 
 
Figure 2: Workflow used for target identification using Systems and Network pharmacology approach. The pipeline is adapted 
from Ana I, Casas et al. [25]. Briefly, the pipeline consists of 3 interdependent layers of data extraction, the Protein-Metabolite 
Network layer, Protein-Protein Network layer and a Semantic Similarity layer. The Protein-Metabolite layer extracts metabolites 
interacting with the causal targets (TNF for CD and VEGFA for UC) from the Human Metabolome Database (HMDB). For each of 
the metabolites, proteins interacting with them is extracted and “The Integrated Interaction Database” (IID) is used to extract 
protein-protein interactions. The Therapeutic Target Database (TTD) is then used to filter the extracted proteins based on the 
availability of drugs.  The proteins thus extracted that have drugs serves as the input for the Semantic Similarity layer, which 
calculates ontology-based semantic similarity scores using molecular function (MF) annotations. It provides a ranking based on 
the similarity scores [64, 65].  
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IBD-OMICS DATABASE CONTENTS 
 
The HOME tab links to CCFA (The Crohn’s and Colitis Foundation), the widely used resource 
for Crohn’s and Colitis. Within each of the tabs, IBD, Crohn’s and Ulcerative Colitis, we have 
the following information: 
 
All of the information collected for each of the following tabs is based on data mined and validated 
from the literature. 
 
• The Genes tab contains gene centric information. The major sources of this data are from 
NCBI gene database and GWAS. Under the GWAS tab there are two sub-tabs that provide 
a network view of other diseases sharing a common SNP or a common gene with the 
disease (IBD, CD or UC).  
 
• The protein tab provides protein centric information from Uniprot database 
(https://www.uniprot.org/).  
• The SNPs tab provides all the curated SNPs from dbsnp database from NCBI 
(https://www.ncbi.nlm.nih.gov/snp/?term=). 
 
• miRNA tab provides microRNAs which were filtered after literature analysis. These 
miRNAs were further investigated using mirBASE (http://www.mirbase.org/) and 
TarBASE databases. 
http://carolina.imis.athenainnovation.gr/diana_tools/web/index.php?r=tarbasev8%2Fi dex  
 
• The Microarrays tab provides expression analysis from GEO database.  
 
• Biomarker Tab provides literature validated biomarkers. 
 
• Literature Tab provides a direct link to literature articles relating to IBD, UC or CD from 
Pubmed and Medline 
 
• The GDSome (GWAS-DiseaSome) tab is a tool that leverages the GWAS database by 
allowing users to search for SNP (rs identifier), Gene, or disease of interest—returning all 
diseases related to the search terms, either by common gene or common SNP. For instance, 
searching the GWAS Diseasome for the disease, Crohn’s Disease, by common gene, we 
return 186 results, 62 unique diseases/traits associated by gene.  This can then be used to 
create disease networks to better visualize how certain diseases correspond to one another. 
 
• The UDSome (Uniprot-DiseaSome) tab is a tool that leverages the Uniprot database by 
allowing users to search for SNP (rs identifier), Gene, or disease of interest—returning all diseases 
related to the search terms, either by common gene or common SNP. For instance, searching the 
UDSome for Crohn’s Disease, by common gene, we return 186 results.   
 
Both UDSome and GDSome enable us to see disease associations by mining the databases 
in their entirety that is otherwise not possible.  
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